PMID: 8961367Oct 1, 1996Paper

Role of radiation therapy in clinical hormonally-active pituitary adenomas

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
R W TsangW J Simpson

Abstract

The outcome following radiation therapy (RT) of hormonally-active pituitary adenomas was assessed. The purpose of this analysis was to determine the control rate after radiation, identify any prognostic factors and evaluate the late toxicity. From 1972 to 1986, 145 patients received RT for hormonally-active pituitary adenomas. The median age was 39 years (range 15-76), with 81 males and 64 females. There were 52 patients with acromegaly, 64 with prolactinoma, and 29 with Cushing's disease. The median follow-up was 7.3 years. RT was given as primary treatment in 17 patients, after initial surgery in 65 patients, and as part of salvage therapy in 63 patients. The median total dose was 50 Gy (daily fraction: 2 Gy). Tumor control was defined as normalization of basal hormonal level and lack of progression of adenoma assessed by imaging studies. The following factors were analyzed for prognostic significance in tumor control: age, sex, tumor type, direction of tumor extension, radiation dose, and radiation field size. The 10-year actuarial proportion of patients with persistent elevated hormone level were 61% following RT alone, and 44% with the addition of medical management. The progression-free rate was 96% at 10 years. Of the 20...Continue Reading

Citations

May 14, 2005·International Journal of Radiation Oncology, Biology, Physics·Philippe ColinPascal Rousseaux
Nov 10, 1998·Lancet·A Colao, G Lombardi
Sep 16, 2003·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Alfons C M van den BerghJan Willem R Pott
Apr 20, 1999·Endocrinology and Metabolism Clinics of North America·M E Molitch
Sep 27, 2001·Endocrinology and Metabolism Clinics of North America·M E Molitch
Sep 5, 2008·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Volker W Stieber
Nov 19, 2010·Radiation Oncology·Douglas G CastroMiguel M Canteras
May 6, 2005·Treatments in Endocrinology·Johan Verhelst, Roger Abs
May 7, 2013·Surgical Neurology International·Rohan R LallJames P Chandler
May 18, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·J R AndersonN Sarkies
Feb 15, 2005·International Journal of Radiation Oncology, Biology, Physics·Sun Ha PaekDavid W Andrews
Dec 21, 2010·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Lana A Del PortoAndrew H Kaye
Jun 16, 2009·European Journal of Internal Medicine·Marleen KarsJohannes A Romijn
Jan 30, 2008·Endocrinology and Metabolism Clinics of North America·Michael Brada, Petra Jankowska
Oct 30, 2007·Neurologic Clinics·Volker W Stieber, Minesh P Mehta
Aug 10, 2007·Clinical Neurology and Neurosurgery·Amit AgrawalAtul Goel
Nov 7, 2006·International Journal of Radiation Oncology, Biology, Physics·Heath B MackleyJohn H Suh
Nov 18, 2005·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Pier Giorgio Crosignani
Nov 1, 2005·International Journal of Radiation Oncology, Biology, Physics·Brian B RonsonJerry D Slater
Dec 12, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·J C WilliamsM G Castro
May 26, 2006·Neurosurgery·Bernd M HofmannRudolf Fahlbusch
Jan 26, 2000·American Journal of Audiology·R S Haggard, M A Primus
Jan 27, 2005·Neurosurgical Focus·Thomas C Witt
Jul 20, 2005·Treatments in Endocrinology·Thankama Ajithkumar, Michael Brada
Jan 16, 2007·European Journal of Endocrinology·F CastinettiT Brue
Jun 10, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Robert M StarkeJason P Sheehan
Feb 22, 2012·Clinical Medicine Insights. Oncology·Ahmed RizkTsambika Psaras
Mar 1, 2012·Expert Review of Endocrinology & Metabolism·Farshad NassiriRicardo V Lloyd
Nov 27, 2018·Neurosurgery·Jennifer VogelRobert A Lustig
Apr 11, 2019·European Journal of Endocrinology·Frederic CastinettiOskar Ragnarsson
May 18, 2006·Endocrine Reviews·Mary P GillamAnnamaria Colao
Apr 1, 2009·Postgraduate Medicine·Mark Hornyak, William T Couldwell
Mar 17, 2009·Journal of Experimental & Clinical Cancer Research : CR·Heng WanShubin Yuan
Feb 9, 2011·Nature Reviews. Endocrinology·Nicholas A TritosBrooke Swearingen
Nov 1, 2005·Neurosurgical Focus·John A Jane
Jun 26, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Michael D CusimanoKalman Kovacs
Dec 2, 1998·Journal of Neurosurgery·P BreenA J Martinez
Nov 22, 2007·The Journal of Clinical Endocrinology and Metabolism·Joshua H PetitJay S Loeffler
Sep 29, 2006·Expert Review of Anticancer Therapy·Mark E Molitch
Apr 26, 2008·Pituitary·Mary Lee Vance
Feb 26, 2014·Expert Review of Neurotherapeutics·Michael E IvanManish K Aghi
Sep 18, 2012·Radiation Oncology Journal·Chai Hong RimChul Yong Kim
Dec 3, 2015·International Ophthalmology Clinics·Chisaroka W Echendu, Larry S Carpenter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.